RegulatoryMay 26, 2026, 04:13 PM
Insulet Issues Omnipod Medical Device Correction; $50M Cost
AI Summary
Insulet Corporation announced a voluntary Medical Device Correction for specific lots of Omnipod® products due to a manufacturing issue causing cannula tears and potential insulin under-delivery. This action, separate from a prior correction, affects approximately 7 million Pods, with 60% already consumed or expired. The company expects to incur up to $50 million in costs in 2026, which will be excluded from adjusted results, but does not anticipate disruption to customer shipments or changes to its 2026 guidance or long-term growth profile.
Key Highlights
- Insulet issues voluntary Medical Device Correction for Omnipod® products.
- Affects approximately 7 million Pods; 60% already consumed or expired.
- Manufacturing issue caused cannula tears, leading to insulin under-delivery.
- Expects up to $50 million in costs in 2026, excluded from adjusted results.
- 24 serious adverse events reported (hospitalization, DKA); no deaths.
- No anticipated disruption to customer shipments or product availability.
- No change to 2026 guidance or long-term growth profile.
Price Impact
More from PODD